Allogene Therapeutics Q4 2023 GAAP EPS $(0.51) Misses $(0.46) Estimate, Sales $21.000K Miss $23.571K Estimate
Allogene Therapeutics Q4 2023 GAAP EPS $(0.51) Misses $(0.46) Estimate, Sales $21.000K Miss $23.571K Estimate
Allogene Therapeutics 2023年第四季度GAAP每股收益（0.51美元）未達到預期（0.46美元），銷售額爲21.0萬美元，低於23.571萬美元的預期
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.46) by 10.87 percent. This is a 23.88 percent increase over losses of $(0.67) per share from the same period last year. The company reported quarterly sales of $21.000 thousand which missed the analyst consensus estimate of $23.571 thousand by 10.91 percent. This is a 19.23 percent decrease over sales of $26.000 thousand the same period last year.
Allogene Therapeutics（納斯達克股票代碼：ALLO）公佈的季度虧損爲每股0.51美元，比分析師普遍預期的0.46美元（0.46美元）低10.87％。這比去年同期每股虧損0.67美元（0.67美元）增長了23.88％。該公司公佈的季度銷售額爲21,000美元，比分析師普遍預期的23,571美元低10.91％。這比去年同期的26,000美元的銷售額下降了19.23％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。